Last deal

$7M

Amount

Venture - Series Unknown

Stage

17.02.2022

Date

3

all rounds

$36.94M

Total amount

date founded

Financing round

General

About Company
Cellics develops innovative biomimetic nanomedicines to treat and prevent diseases.

Industry

Sector :

Subsector :

founded date

01.01.2014

Number of employees

Company Type

For Profit

Last funding type

Venture - Series Unknown

IPO status

Private

Description

The company focuses on autoimmune and inflammatory diseases, difficult-to-treat infectious diseases, and vaccine development. Their nanosponge technology utilizes a unique mechanism to treat animal venoms and rare diseases caused by virulent factors. Cellics is currently advancing its lead product candidate CTI-005 to human clinical trials for bacterial pneumonia treatment. Founded in 2014, the San Diego-based biotechnology company aims to use its Cellular Nanoparticle platform technology to improve the lives of patients with high unmet medical needs.
Contacts

Contact Email

Phone number

Social url

Similar Companies
1000

Azaya Therapeutics

Azaya Therapeutics develops nanotechnology for advanced cancer treatment.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

San Antonio, TX, USA
Nanoligent

Nanoligent

Nanoligent is a biotech company developing targeted-therapeutic biologics for diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Nanotechnology

Location

Barcelona, Spain

total rounds

2

total raised

$2.6M
Minerva Biotechnologies

Minerva Biotechnologies

Minerva Biotechnologies develops cancer immunotherapies and stem cell technologies for regenerative medicine.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Waltham, MA, USA

total rounds

7

total raised

$70.02M
S.Biomedics

S.Biomedics

S.Biomedics is a company that develops somatic cell therapy for the safe treatment of intractable diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

Seoul, South Korea

total rounds

1

Financials

Funding Rounds
5
3

Number of Funding Rounds

$36.94M

Money Raised

Their latest funding was raised on 17.02.2022. Their latest round Venture - Series Unknown

Date 
Funding Round 
Investors 
Money Raised 
Lead 
17.02.2022
$7M
21.10.2020
1
$3.94M
26.05.2020
$13M
CARB-X

CARB-X

CARB-X is a global non-profit partnership accelerating antibacterial R&D.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Boston, MA, USA

count Of Investments

114

count Of Exists

8
Co-Investors
Investors
1
1

Number of lead investors

1

Number of investors

Investor 
Lead 
Round 
Partners 
CARB-X

CARB-X

CARB-X is a global non-profit partnership accelerating antibacterial R&D.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Boston, MA, USA

count Of Investments

114

count Of Exists

8
Erin Duffy

Erin Duffy

Erin Duffy is an R&D Chief at CARB-X.

People

Founders
1
Liangfang Zhang
Liangfang Zhang

Liangfang Zhang

Liangfang Zhang received his Ph.D. in Chemical & Biomolecular Engineering from the University of Illinois at Urbana-Champaign in 2006. He was a postdoctoral associate in the laboratory of Prof. Robert Langer at MIT during 2006-2008. He received his M.S. and B.E. degrees in Chemical Engineering from Tsinghua University in 2002 and 2000, respectively. He joined UC San Diego as an Assistant Professor in July 2008 and was promoted to an Associate Professor with tenure in March 2012 and to Professor in July 2014. Prof. Zhang has published 128 peer-reviewed articles and holds 43 issued/pending patents. He received the Victor K. LaMer Award from the American Chemistry Society in 2009, the Unilever Award from the American Chemistry Society in 2012, the MIT Technology Review’s TR35 Innovator Award in 2013, the Allan P. Colburn Award from the American Institute of Chemical Engineers in 2014, and was elected to the Fellow of the American Institute of Medical and Biological Engineering in 2015. Prof. Zhang was selected as one of The Brilliant 10 in all US science and engineering fields by the magazine Popular Science in 2016.

current job

Cellics Therapeutics
Cellics Therapeutics

organization founded

2

Liangfang Zhang

Employee Profiles
2
Liangfang Zhang

Liangfang Zhang

Founder

Huiqing Zhu

Huiqing Zhu

CEO

Activity

Recent News
0